CTLA4 and cancer: Recent attempts in breast cancer to elucidate the role of EMT in cancer cells’ ability to facilitate an immunosuppressive TME have shown that mesenchymal cancer cells express low levels of MHC I and are associated with infiltration of regulatory T cells (Treg)27 and resistance to anti-CTLA4 therapy3.